Zimmer Biomet (NYSE:ZBH) Upgraded by Wall Street Zen to “Buy” Rating

Wall Street Zen upgraded shares of Zimmer Biomet (NYSE:ZBH) from a hold rating to a buy rating in a research note released on Saturday morning.

A number of other brokerages have also weighed in on ZBH. Evercore ISI upgraded Zimmer Biomet from an “in-line” rating to an “outperform” rating and raised their price objective for the company from $94.00 to $120.00 in a research report on Monday, January 5th. Stifel Nicolaus set a $110.00 target price on shares of Zimmer Biomet in a report on Wednesday, November 5th. The Goldman Sachs Group lowered shares of Zimmer Biomet from a “neutral” rating to a “sell” rating and set a $93.00 price target on the stock. in a report on Friday, January 9th. Weiss Ratings reissued a “hold (c-)” rating on shares of Zimmer Biomet in a research report on Wednesday, October 8th. Finally, UBS Group decreased their target price on Zimmer Biomet from $96.00 to $88.00 and set a “sell” rating for the company in a report on Thursday, November 6th. One investment analyst has rated the stock with a Strong Buy rating, eight have assigned a Buy rating, eleven have assigned a Hold rating and three have given a Sell rating to the company. According to data from MarketBeat, the stock presently has an average rating of “Hold” and a consensus target price of $107.33.

Zimmer Biomet Price Performance

ZBH stock opened at $87.42 on Friday. The company has a debt-to-equity ratio of 0.59, a quick ratio of 1.39 and a current ratio of 2.43. The firm has a 50 day moving average price of $91.59 and a 200-day moving average price of $96.48. Zimmer Biomet has a 52-week low of $85.33 and a 52-week high of $114.44. The firm has a market capitalization of $17.32 billion, a price-to-earnings ratio of 21.64, a PEG ratio of 2.23 and a beta of 0.62.

Zimmer Biomet (NYSE:ZBH) last announced its quarterly earnings data on Wednesday, November 5th. The medical equipment provider reported $1.90 earnings per share for the quarter, topping analysts’ consensus estimates of $1.88 by $0.02. Zimmer Biomet had a net margin of 10.05% and a return on equity of 12.85%. The company had revenue of $2 billion during the quarter, compared to analyst estimates of $2.01 billion. During the same period in the previous year, the business earned $1.74 EPS. The firm’s revenue for the quarter was up 9.6% on a year-over-year basis. Zimmer Biomet has set its FY 2025 guidance at 8.100-8.300 EPS. Equities research analysts forecast that Zimmer Biomet will post 8.22 EPS for the current fiscal year.

Zimmer Biomet Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Friday, January 30th. Stockholders of record on Tuesday, December 30th will be given a dividend of $0.24 per share. The ex-dividend date is Tuesday, December 30th. This represents a $0.96 dividend on an annualized basis and a dividend yield of 1.1%. Zimmer Biomet’s dividend payout ratio (DPR) is 23.76%.

Institutional Inflows and Outflows

Hedge funds have recently modified their holdings of the stock. Key Financial Inc increased its stake in Zimmer Biomet by 164.6% during the 3rd quarter. Key Financial Inc now owns 262 shares of the medical equipment provider’s stock worth $26,000 after buying an additional 163 shares in the last quarter. Cullen Frost Bankers Inc. increased its position in shares of Zimmer Biomet by 66.7% during the third quarter. Cullen Frost Bankers Inc. now owns 290 shares of the medical equipment provider’s stock worth $29,000 after purchasing an additional 116 shares in the last quarter. Root Financial Partners LLC purchased a new stake in shares of Zimmer Biomet during the third quarter worth approximately $31,000. Cary Street Partners Investment Advisory LLC raised its stake in Zimmer Biomet by 83.7% in the 2nd quarter. Cary Street Partners Investment Advisory LLC now owns 327 shares of the medical equipment provider’s stock valued at $30,000 after purchasing an additional 149 shares during the last quarter. Finally, Mather Group LLC. purchased a new position in Zimmer Biomet in the 3rd quarter valued at $36,000. Institutional investors and hedge funds own 88.89% of the company’s stock.

About Zimmer Biomet

Zimmer Biomet (NYSE: ZBH) is a global medical device company focused on musculoskeletal healthcare. Headquartered in Warsaw, Indiana, the company designs, manufactures and markets a broad portfolio of products used to treat joint disorders, bone disorders and related conditions. Its customer base includes orthopaedic and dental surgeons, hospitals, ambulatory surgery centers and other healthcare providers that rely on implants, instruments and related services for reconstructive and restorative procedures.

The company’s product offerings span joint replacement systems for hips, knees and shoulders; trauma and extremities implants; spine and thoracic solutions; dental and craniomaxillofacial implants and prosthetics; and sports medicine devices.